Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year’s big run-up, this clinical-stage biotech stock could still be a gold mine for growth investors.
